Ustekinumab

What is Ustekinumab?

Ustekinumab is a human monoclonal antibody, a type of biologic medication, widely known by its brand name Stelara. It falls under the ATC code I04, classifying it as a selective immunosuppressant. This potent medication is designed to treat several chronic autoimmune and inflammatory conditions by specifically modulating the immune system's response, offering a targeted approach to disease management.

As a biologic, Ustekinumab is a complex protein produced using living organisms, distinguishing it from traditional small-molecule drugs. Its primary function is to interfere with specific inflammatory pathways, thereby reducing chronic inflammation and alleviating symptoms in conditions where the immune system mistakenly attacks healthy tissues.

Mechanism of Action

The therapeutic efficacy of Ustekinumab is attributed to its highly specific mechanism of action, which targets two key pro-inflammatory cytokines: interleukin-12 (IL-12) and interleukin-23 (IL-23). These naturally occurring proteins are pivotal in regulating immune responses and inflammation, and their overactivity contributes significantly to various autoimmune diseases.

• IL-12 and IL-23 are central to the pathogenesis of several immune-mediated inflammatory diseases.
• Ustekinumab binds to the p40 protein subunit, which is common to both IL-12 and IL-23.
• This binding prevents IL-12 and IL-23 from interacting with their specific receptors on immune cells.
• The blockade disrupts downstream signaling pathways that drive inflammation, including the differentiation of T-helper 1 (Th1) and T-helper 17 (Th17) cells.
• This action leads to a significant reduction in the inflammatory cascade, decreasing disease activity and improving symptoms for patients.

Medical Uses

Ustekinumab is approved for the treatment of several chronic inflammatory and autoimmune diseases where its targeted mechanism effectively improves patient outcomes.

• Primary Uses:
  • Moderate to Severe Plaque Psoriasis: For adults suitable for phototherapy or systemic therapy.
  • Psoriatic Arthritis: For adults, used alone or in combination with methotrexate.
  • Moderate to Severe Crohn's Disease: For adults who have failed or are intolerant to conventional therapy or a TNFα antagonist.
  • Moderate to Severe Ulcerative Colitis: For adults who have failed or are intolerant to conventional therapy or a TNFα antagonist.

Dosage

The dosage regimen for Ustekinumab varies by indication and, in some cases, patient body weight. It is administered via subcutaneous injection for maintenance, with an initial intravenous (IV) dose for Crohn's disease and ulcerative colitis induction.

Side Effects

As with all medications, Ustekinumab can cause side effects, though not everyone experiences them. Patients should discuss any concerns with their healthcare provider.

• Common Side Effects:
  • Upper respiratory infections (e.g., common cold, sinus infection)
  • Headache, fatigue
  • Injection site reactions (redness, pain, swelling)
  • Nausea, diarrhea, sore throat
• Rare but Serious Side Effects (require immediate medical attention):
  • Serious infections: Increased risk of bacterial, fungal, or viral infections, including tuberculosis (TB).
  • Malignancies: Potential increased risk of certain cancers, including non-melanoma skin cancer.
  • Allergic reactions: Severe hypersensitivity reactions, including anaphylaxis.
  • Reversible Posterior Leukoencephalopathy Syndrome (RPLS): A rare neurological disorder.
  • Pneumonitis: Inflammation of the lungs.

Warnings

Prior to initiating Ustekinumab treatment, a thorough medical evaluation is crucial to ensure its safe and appropriate use. Certain conditions may contraindicate its use or necessitate careful monitoring.

• Active Serious Infections: Do not initiate in patients with clinically important active infections until resolved or adequately treated.
• Tuberculosis (TB): Patients must be evaluated for TB infection. Latent TB requires treatment before starting Ustekinumab.
• Malignancy: Consider risks and benefits in patients with a history of malignancy.
• Hypersensitivity: Contraindicated in patients with known severe hypersensitivity to Ustekinumab or its excipients.
• Live Vaccines: Avoid concurrent administration of live vaccines.

Disclaimer: This article provides general medical information and is not a substitute for professional medical advice, diagnosis, or treatment. Always seek the advice of your physician or other qualified health provider with any questions you may have regarding a medical condition or before starting any new treatment. Do not disregard professional medical advice or delay in seeking it because of something you have read in this article. The information provided here is for educational purposes only and should not be used for self-diagnosis or self-treatment.